In the largest-ever drug safety settlement case of a generic drugmaker in the US, Ranbaxy Laboratories Ltd. agreed to pay $500-million (INR 27,427.7 million) penalty to the US government to settle a criminal and civil lawsuit, which leveled charges of falsifying data from its drug facilities and shoddy manufacturing practices against it. Of this, criminal fine and forfeiture accounted for $150 million (INR 8,228.3 million) and $350 million (INR 19,196.0 million) would be paid by Ranbaxy to settle civil claims under False Claims Act. Ranbaxy USA, a subsidiary of Ranbaxy Labs, guilty on account of three violations to US's Food, Drug and Cosmetic Act (FDCA) and accepted that it had knowingly made material false statements to the US Food and Drug Administration.

Ranbaxy Laboratories Ltd. announced unaudited consolidated and standalone earnings results for the first quarter ended March 31, 2013. For the quarter, on consolidated basis, the company reported net sales (net of excise duty) of INR 24,398.24 million compared to INR 37,089.71 million a year ago. Total income from operations of INR 25,005.51 million compared to INR 37,813.12 million a year ago. Income from operations before other income, finance costs and exceptional items was INR 752.48 million compared to INR 10,112.76 million a year ago. Profit from ordinary activities before tax was INR 1,669.92 million compared to INR 13,980.46 million a year ago. Profit for the period was INR 1,316.54 million compared to INR 12,606.22 million a year ago. Diluted EPS was INR 2.97 compared to INR 29.51 a year ago. For the quarter, on standalone basis, the company reported net sales (net of excise duty) of INR 13,278.77 million compared to INR 18,102.28 million a year ago. Total income from operations of INR 13,816.36 million compared to INR 18,664.72 million a year ago. Loss from operations before other income, finance costs and exceptional items was INR 134.17 million compared to income from operations before other income, finance costs and exceptional items of INR 4,456.74 million a year ago. Profit from ordinary activities before tax was INR 701.47 million compared to INR 8,272.31 million a year ago. Profit for the period was INR 701.47 million compared to INR 8,272.31 million a year ago. Diluted EPS was INR 1.66 compared to INR 19.58 a year ago.

Ranbaxy Laboratories Ltd. reported sales results for the first quarter of 2013. For the quarter sales totaled INR 24,398 million.